XERS Xeris Pharmaceuticals Inc

Price (delayed)

$2.49

Market cap

$369.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$575.16M

Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

Highlights
XERS's quick ratio is up by 46% since the previous quarter and by 10% year-on-year
The gross profit has grown by 42% YoY and by 5% from the previous quarter
XERS's EPS is up by 19% year-on-year but it is down by 2.2% since the previous quarter
The net income has grown by 17% YoY but it has contracted by 3.4% from the previous quarter
XERS's equity has dropped by 131% year-on-year and by 35% since the previous quarter
The debt has grown by 35% YoY and by 17% from the previous quarter

Key stats

What are the main financial stats of XERS
Market
Shares outstanding
148.26M
Market cap
$369.16M
Enterprise value
$575.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
Earnings
Revenue
$171.36M
EBIT
-$37.92M
EBITDA
-$24.73M
Free cash flow
-$43.38M
Per share
EPS
-$0.46
Free cash flow per share
-$0.31
Book value per share
-$0.07
Revenue per share
$1.22
TBVPS
$1.47
Balance sheet
Total assets
$336.62M
Total liabilities
$345.79M
Debt
$268.7M
Equity
-$9.18M
Working capital
$100.2M
Liquidity
Debt to equity
-29.28
Current ratio
2.37
Quick ratio
1.71
Net debt/EBITDA
-8.33
Margins
EBITDA margin
-14.4%
Gross margin
82.9%
Net margin
-37.6%
Operating margin
-26.2%
Efficiency
Return on assets
-19.6%
Return on equity
-16,662.6%
Return on invested capital
-12.9%
Return on capital employed
-14.4%
Return on sales
-22.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XERS stock price

How has the Xeris Pharmaceuticals stock price performed over time
Intraday
5.96%
1 week
16.9%
1 month
13.18%
1 year
-1.97%
YTD
5.96%
QTD
10.67%

Financial performance

How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$171.36M
Gross profit
$142.06M
Operating income
-$44.98M
Net income
-$64.4M
Gross margin
82.9%
Net margin
-37.6%
Xeris Pharmaceuticals's operating margin has soared by 52% YoY and by 2.2% from the previous quarter
The gross profit has grown by 42% YoY and by 5% from the previous quarter
The net margin has grown by 41% YoY
The company's revenue rose by 41% YoY and by 4.5% QoQ

Growth

What is Xeris Pharmaceuticals's growth rate over time

Valuation

What is Xeris Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
XERS's EPS is up by 19% year-on-year but it is down by 2.2% since the previous quarter
XERS's equity has dropped by 131% year-on-year and by 35% since the previous quarter
XERS's price to sales (P/S) is 89% less than its 5-year quarterly average of 18.0 and 3.5% less than its last 4 quarters average of 2.0
The company's revenue rose by 41% YoY and by 4.5% QoQ

Efficiency

How efficient is Xeris Pharmaceuticals business performance
The return on invested capital has surged by 61% year-on-year and by 6% since the previous quarter
XERS's ROS has soared by 56% year-on-year
The return on assets rose by 19% year-on-year but it has declined by 2.6% since the previous quarter

Dividends

What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XERS.

Financial health

How did Xeris Pharmaceuticals financials performed over time
The total assets is 2.7% less than the total liabilities
XERS's quick ratio is up by 46% since the previous quarter and by 10% year-on-year
XERS's current ratio is up by 45% since the previous quarter and by 17% year-on-year
XERS's equity has dropped by 131% year-on-year and by 35% since the previous quarter
The debt has grown by 35% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.